South Korean scientists have achieved excellent results in the treatment of COVID-19 with antibodies – it turned out to be effective and safe.
The study by the South Korean pharmaceutical company Celltrion Inc involved 1,315 people. The tests, starting in January, were carried out in 13 countries – South Korea, Romania, USA, Spain and others. According to Celltrion, the method in a Phase 3 global clinical trial will shorten treatment and recovery times by 5 days. In 70%, the treatment was effective against severe symptoms, including those with serious underlying medical conditions, AMPE reports.
The antibody treatment was conditionally approved in South Korea in February and became the first topical treatment for the novel coronavirus. The company notes that it will seek full approval based on the test results obtained. On the back of the latest announcements, Celltrion’s stock is up 5.6% this morning.